PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today ...
Qure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the pricing of its underwritten public offering of 4 ...
Teos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today ...
A powerful, new framework called "Annotatability" has been developed by researchers at the Hebrew University of Jerusalem to address a major challenge in biological research -- identifying mismatches ...
Planegg-Martinsried, Germany - Formycon AG (FSE: FYB, Prime Standard, “Formycon”) and its commercialization partner Fresenius Kabi announce that Health Canada has issued a “Notice of Compliance” (NOC) ...
NEW YORK, NY / ACCESSWIRE / January 8, 2025 / Bionoid Pharma, Inc. ("Bionoid") (OTC PINK:BINP) is pleased to announce the generation of over $100,000 in revenue following the signing of a Binding ...
JACKSONVILLE, FLORIDA / ACCESSWIRE / January 8, 2025 / TriageLogic, a leader in telehealth triage solutions, has announced two major advancements for 2024: the launch of TriageIntelligence™, an ...
SHELTON, CT / ACCESSWIRE / January 8, 2025 / Dr. Anil Diwan, President of NanoViricides, Inc. (NYSE American: NNVC) (the "Company"), comments on the many viruses that could cause pandemics that are ...
ProBioGen today announces the expansion of both protein and virus manufacturing at its Berlin headquarters. This includes the commissioning of an additional 1000L-scale GMP production line for ...
Cambridge Cognition Holdings plc (AIM: COG), the brain health software group, congratulates Bristol Myers Squibb, the global biopharmaceutical company, for its recent FDA approval of Cobenfy (KarXT™ ...
Antag Therapeutics (“Antag” or “the company”), a biopharmaceutical company pioneering novel treatments for obesity, today announced the appointment of Joerg Moeller, MD, PhD, as Chief Executive ...
Commit Biologics appoints accomplished R&D executive, Dr Janine Schuurman, to its Board of Directors
Commit Biologics (“Commit”), a pioneer in the activation of the complement system to treat cancer and autoimmune disease, today announces the appointment of Janine Schuurman, Ph.D. to its Board of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback